[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572117":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":28,"collaborators":10,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":10,"eligibilityCriteria":37,"healthyVolunteers":34,"sex":38,"minAge":39,"maxAge":10,"enrollmentInfo":40,"targetDuration":10,"studyType":43,"phases":10,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Low-risk group",null,"Brain metastasis risk prediction model score 0-4 points.",{"label":13,"type":10,"description":14,"interventionNames":10},"Medium-risk group","Brain metastasis risk prediction model score 5-10 points.",{"label":16,"type":10,"description":17,"interventionNames":10},"High-risk group","Brain metastasis risk prediction model score \\>10 points.",[19,24],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Moheb I Moheb Ibrahim Melek, MSc in clinical oncology","CONTACT","+201092655523","mohebmelek@med.aun.edu.eg",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},"Doaa Ali Gamal, MD in clinical oncology","+201118118806","doaagamaal@aun.edu.eg",{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Moheb Ibrahim Melek","Clinical oncology specialist","100572117","validity-of-brain-metastasis-risk-predictive-model-in-hormone-positive-breast-cancer-patients-100572117",false,"NCT06729099","Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients","Inclusion Criteria:\n\n* Confirmed diagnosis of HR-positive primary invasive breast cancer.\n\nExclusion Criteria:\n\n1. Patients if they were diagnosed with brain metastases at the time of initial breast cancer diagnosis or within the subsequent three months.\n2. Bilateral breast cancer.\n3. Synchronic cancer (i.e., lung cancer, melanoma).\n4. Paitents presenting neurologic symptoms without follow-up or lacking a contrast-enhanced magnetic resonance image (cMRI).\n5. Incomplete clinicopathological information at the time of diagnosis.","FEMALE","18 Years",{"count":41,"type":42},128,"ESTIMATED","OBSERVATIONAL","This study aims to validate a prediction model of brain metastasis risk for females with HR+ breast cancer by using variables collected at diagnosis.",[46],"Breast Cancer, Estrogen Receptor-Positive",[48,49,50,51],"breast cancer","Hormonal receptor positive","brain metastasis risk","Prediction model","NOT_YET_RECRUITING","2024-12-08",{"date":55,"type":56},"2024-12-11","ACTUAL",{"date":58,"type":42},"2025-01",{"date":60,"type":42},"2027-06",{"name":5,"class":6}]